Form 4: Opus Genetics CFO Executes Automatic Tax-Related Stock Sale

Sentiment:

Statement of Changes in Beneficial Ownership


CFO Robert E. Gagnon sold 7,842 shares of Opus Genetics to cover tax obligations related to restricted stock unit vesting.

Summary

  • Robert E. Gagnon, Chief Financial Officer of Opus Genetics, Inc., sold 7,842 shares of common stock on April 23, 2026.
  • The shares were sold at a weighted average price of $5.1846 per share.
  • Following the transaction, the reporting person retains beneficial ownership of 592,158 shares.
  • The sale was executed automatically to satisfy tax withholding obligations resulting from the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative and mandatory for tax purposes.

Positives

  • The transaction was non-discretionary, indicating it was not a signal of management's outlook on the company's future performance.

Negatives

  • Reduction in the direct equity stake held by the Chief Financial Officer.

Risks

  • None identified; the transaction is a standard administrative procedure for tax compliance.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Management Comments

  • The transaction does not represent a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that automatic sell-to-cover transactions are standard corporate governance practices for executives to manage tax liabilities upon the vesting of equity compensation, and they generally do not reflect changes in management sentiment regarding company prospects.

Comparison to Industry Standards

  • The transaction aligns with standard executive compensation and tax compliance practices observed across the biotechnology and pharmaceutical sectors.

Stakeholder Impact

  • Minimal impact on shareholders as the sale was non-discretionary and related to tax obligations.

Next Steps

  • None specified.

Key Dates

DateDescription
04/23/2026Date of the stock sale transaction.
04/27/2026Date the Form 4 was signed and filed.

Keywords

Opus Genetics, IRD, Form 4, Insider Trading, CFO, Tax Withholding, Equity Vesting

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.